Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sharp TherapeuticsTSXV:SHRX 14 Shareholder Yield % is 0.26% as of Dec. 2025, which is 99% below its 10-year median of 31.59. GuruFocus rates TSXV:SHRX with a GF Score™ of 14/100. Among 1,297 Biotechnology companies, Sharp Therapeutics ranks better than 70.24% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Sharp Therapeutics's Shareholder Yield % was 0.26%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Sharp Therapeutics Shareholder Yield % Related Terms
Sharp Therapeutics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Sharp Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:SHRX vs VRTX, REGN, ALNY: Shareholder Yield % Comparison
For the Biotechnology subindustry, Sharp Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sharp Therapeutics Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Sharp Therapeutics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Sharp Therapeutics (TSXV:SHRX) has a Shareholder Yield % of 0.26% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Sharp Therapeutics and its competitors. This is 99% below median its historical median of 31.59. Over the past decade, Sharp Therapeutics' Shareholder Yield % has ranged from 0.09 to 63.09. According to the industry distribution chart, Sharp Therapeutics ranks #386 out of 1297 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Sharp Therapeutics' Shareholder Yield % too high?
Sharp Therapeutics' current Shareholder Yield % of 0.26% is 99% below median its 10-year median of 31.59. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 63.09. Based on the distribution chart, Sharp Therapeutics ranks #386 out of 1297 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sharp Therapeutics ranks #386 out of 1297 companies for Shareholder Yield %. This puts Sharp Therapeutics in the upper half of its industry. Historically, Sharp Therapeutics' own Shareholder Yield % has ranged from 0.09 to 63.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Sharp Therapeutics and its competitors. Sharp Therapeutics's current Shareholder Yield % is 0.26%, which is 99% below median its own 10-year median of 31.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Shareholder Yield % of 0.26%. The current Shareholder Yield % is 0.26%, which is 99% below median its 10-year median of 31.59. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Shareholder Yield % is 0.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score
Get the complete analysis for TSXV:SHRX
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SHRX has been successfully added to your 
